SLE systemic lupus erythematosus
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients full-filling the ACR criteria for systemic lupus erythematosus Controles: 18 years or older
Exclusion criteria
Exclusion criteria: Patients: patients with proven other auto-immune disorders, pregnancy and malignancy Controls: a history or presence of auto-immune disease and current use of immunosupressants or pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The expression of IL-7, TSLP, CD30L and their receptors in peripheral blood and urine of patients with SLE as compared to healthy controls. | — |
Secondary
| Measure | Time frame |
|---|---|
| The longitudinal approach will be used to assess the correlation between the changes in IL-7, TSLP and CD30L and their receptor with the changes in disease activity and immunologic parameters. Identify biomarkers different from healthy controls that reflect disease activity and can be play a role in the pathogenesis of SLE. The results of the proposed studies may contribute to a future treatment strategy by blockade of some of the investigated inflammatory mediators. Third objective: Leucocytes will also be stored for DNA isolation, which will be used for analyses of polymorphic sites that might be involved in regulation of transcription of the investigated molecules | — |
Countries
Netherlands
Outcome results
None listed